At the Vaccine Center, part of the Department of Medicine’s Division of Infectious Diseases and Immunology at NYU Langone Health, renowned experts in vaccine research merge basic science, clinical studies, and public health outreach to prevent the spread of disease.
Our inaugural director, Mark J. Mulligan, MD, has been an international leader in infectious disease research programs for more than three decades, and his pioneering work has profoundly advanced the field.
Using the latest technologies from fields such as epidemiology, immunology, and microbiology, we lead collaborative research projects designed to identify safe and effective vaccines for infectious illnesses including measles and influenza. We also develop vaccines for noninfectious conditions including cancers, autoimmune disorders, brain conditions, and chronic diseases.
Our goals reach beyond just discovering the next vaccine. We care deeply about protecting public health, and collaborate with communities to improve how we communicate information about vaccines. We aim to increase access to care and combat vaccine hesitancy in New York City and around the world.
As an international hub for cutting-edge research, the Vaccine Center was able to respond immediately as New York City became the epicenter of the 2019 coronavirus disease (COVID-19) pandemic. With our expertise and resources, we were able to respond quickly to this public health emergency by launching important clinical trials in vaccine and treatment research.
In 2020, the Vaccine Center was established as a Vaccine and Treatment Evaluation Unit (VTEU) by the National Institute of Allergy and Infectious Diseases (NIAID). We are honored to join the Infectious Diseases Clinical Research Consortium, a clinical trials network made up of 10 VTEU sites nationwide.
NYU Langone was chosen as a trial site for experimental COVID-19 vaccines thanks in part to the expertise of Dr. Mulligan, who for decades has led infectious disease research programs that have yielded vaccine candidates for HIV and other viruses.
Vaccine Center to Enroll Healthy Volunteers in Clinical Trial for COVID-19 Vaccine
Participate in a COVID-19 Vaccine Clinical Trial
Global Phase 2/3 Clinical Trial for COVID-19 Vaccine Starts at NYU Langone
Executive Order Calls For New Flu Vaccine Research
Join Us for a Discussion About COVID-19 Vaccines
Dr. Mark Mulligan explains the impact of vaccinations: "One measles shot provides immunity to 93% of vaccinated persons, and the recommended two shots provide protection to 97%."